Type: Product
Name: Zytiga
First reported 5 hours ago - Updated 1 hour ago - 1 reports

Tokai pockets $97M in IPO cash to get its cancer drug into Phase III

Cambridge, MA, biotech Tokai Pharmaceuticals ($TKAI) pulled off a $97.2 million Wall Street debut, raising the money it needs to get its three-in-one treatment for prostate cancer into late-stage development.The company moved about 6.5 million shares ... [Published FierceBiotech - 5 hours ago]
First reported Sep 11 2014 - Updated Sep 12 2014 - 5 reports

Medivation, Now The Deluge

By Mrs. BullBear :In August 2012 biotech firm Medivation (NASDAQ: MDVN ) launched prostate cancer drug Xtandi. Since this launch XTANDI has trailed it's competitor in the anti-androgen market, Johnson & Johnson (NYSE: JNJ ) produced Zytiga, due to a ... [Published BioPortfolio - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

J&J trims pension benefits for new hires

Even drugmakers with steamrolling pharma units need to cut costs sometimes, and Johnson & Johnson ($JNJ) fits that bill. To do so, the company will shrink the pension benefits offered to those who are hired--or rehired--after Jan. 1.According to Peter ... [Published FiercePharma - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 7 reports

Pre-chemo nod for Medivation's Xtandi sets up showdown with J&J's Zytiga

Johnson & Johnson's ($JNJ) next-gen prostate cancer pill, Zytiga, has been cruising since it hit the market back in April 2011, but now, it may be vulnerable to market share losses for the first time. The FDA has approved Medivation and Astellas' rival, ... [Published FiercePharma - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

USPTO Issues Patent For GenSpera’s Prostrate Cancer Prodrug

By Cyndi RootGenSpera announced in a press release that the United States Patent and Trademark Office (USPTO) has issued a patent for its prostate cancer prodrug. Patent number 8,822,406, “Tumor Activated Prodrugs,” covers the prodrug’s composition. The ... [Published Bioresearch Online - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

A Top Dividend Stock for Your Portfolio: Johnson & Johnson

Dividend stocks are an essential ingredient to a well-balanced portfolio. Even so, it's important to bear in mind that not all dividend stocks are created equal.When picking over potential dividend candidates, you should look for companies with clean ... [Published Motley Fool Discussion Boards - Sep 10 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Blood test predicts prostate cancer treatment response

A new study has revealed that prostate cancer patients whose tumours have a shortened protein called AR-V7 are less likely to respond to two drugs widely used in treatment.The team at the Johns Hopkins Kimmel Cancer Center analysed two groups of 31 men ... [Published Spire Healthcare - Sep 05 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 3 reports

Exelixis to lay off 70 percent of staff after prostate cancer drug bombs

Exelixis is watching its stock plummet after its experimental drug failed to prolong the lives of men with advanced prostate cancer in an important, late-stage clinical trial.Announcing those bombshell results late Monday, the South San Francisco biotechnology ... [Published San Francisco Chronicle - Sep 02 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 1 reports

Drugs giants in spin cycle

Big drug companies, says Helena McAlpine, are "absolutely taking the piss". The margins on their products are indefensible.If anyone has a right to an opinion on the matter, it's her. McAlpine was first told she had breast cancer in 2009. Two years later, ... [Published The Press NZ - Aug 30 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Zytiga cancer drug denied to Welsh patients

WELSH Conservatives have reacted angrily to the news that another life-extending cancer drug may not be available to patients in Wales.The National Institute for Health and Care Excellence (NICE) has issued final draft guidance on the prostate cancer ... [Published Penarth Times - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Mad at NICE's cancer drug rejections? Look to drugmakers, agency chief says

Political shilly-shallying about the cost of drugs has to end, the chief of the U.K.'s cost-effectiveness agency says. Government officials and politicians need to be up front with the public about one stark fact: The country's health service just can't ... [Published FiercePharma - Aug 25 2014]
First reported Aug 23 2014 - Updated Aug 24 2014 - 1 reports

Drug giant incites war of the sexes

A PR representative for a billion-dollar drug company has set up a health funding battle between men and women by claiming breast cancer sufferers get "gold standard" treatment but men with prostate cancer are "sent home to die".The Prostate Cancer Foundation ... [Published Waikato Times - Aug 23 2014]


...a retirement program that's above average among our peer companies," he wrote in an internal memo seen by The Wall Street Journal's Pharmalot. "… More importantly, it will continue to support our efforts to attract and retain talent to drive innovation and growth across our family of companies, helping us manage for the long term."
"The average duration of treatment should double and the addressable patient population triple in the pre-chemo setting" Sanford Bernstein analyst Geoffrey Porges said in a research note earlier this week
Dr Tomasz Beer, co-principal investigator of the PREVAIL study added: "Furthermore, in the PREVAIL trial, the median time to initiating chemotherapy was delayed by 17 months with enzalutamide treatment as compared to placebo, so the result is a meaningful period of time during which men have their disease controlled without the need for chemotherapy."
...the Prevail trial was very, very compelling, and it shows that the drug is very, very efficacious," Maxim Group analyst Jason Kolbert told IBD. "The fact that it works well and it's very convenient for patients -- it's an oral drug -- and that it's cost-effective compared to a drug likeDendreon 's ( DNDN ) Provenge really are what's driving the marketplace."

More Content

All (128) | News (115) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Tokai pockets $97M in IPO cash to get its cance... [Published FierceBiotech - 5 hours ago]
Tokai Bags $97M For Prostate Cancer Drug in Ups... [Published Xconomy - 6 hours ago]
AR-V7 linked to treatment resistance in castrat... [Published Orthopedics Today - Sep 16 2014]
Studies Help Refine Management of Prostate Cancer [Published The ASCO Post - Sep 15 2014]
J&J trims pension benefits for new hires [Published FiercePharma - Sep 12 2014]
Medivation, Now The Deluge [Published BioPortfolio - Sep 12 2014]
Wall Street Bullish On Medivation, Inc. After X... [Published BioSpace - Sep 12 2014]
West Coast Biotech Roundup: Gates, Orexigen, Me... [Published Xconomy - Sep 12 2014]
Medivation, Now The Deluge [Published Seeking Alpha - Sep 12 2014]
Pre-chemotherapy indication for Xtandi in prost... [Published PMLive - Sep 12 2014]
Xtandi duo boosts rep force for pre-chemo push [Published Medical Marketing And Media - Sep 11 2014]
Medivation Eyes Blockbuster As Cancer Drug Gets... [Published Nasdaq - Sep 11 2014]
Five things for pharma marketers to know: Thurs... [Published Medical Marketing And Media - Sep 11 2014]
Pre-chemo nod for Medivation's Xtandi sets up s... [Published FiercePharma - Sep 11 2014]
USPTO Issues Patent For GenSpera’s Prostrate Ca... [Published Bioresearch Online - Sep 11 2014]
Medivation’s Xtandi Approved For Pre-Chemo Use;... [Published Bidness Etc - Sep 11 2014]
FDA approves new indication for Xtandi [Published Pharmafocus - Sep 11 2014]
Cancer Research UK, Cancer Research Technology ... [Published RCL Advisors - Sep 11 2014]
FDA clears Xtandi for pre-chemo patients [Published Pharma Times - Sep 11 2014]
Medivation Inc's FDA Approval Could be the Deat... [Published Motley Fool - Sep 11 2014]
U.S. FDA approves expanded use of Medivation pr... [Published DailyMe.Com - Sep 11 2014]
U.S. FDA okays expanded use of Medivation prost... [Published Reuters - Sep 10 2014]
Medivation Prostate Cancer Drug Secures Expande... [Published Delco Times - Sep 10 2014]
Medivation Prostate Cancer Drug Secures Expande... [Published TheStreet.com - Sep 10 2014]
A Top Dividend Stock for Your Portfolio: Johnso... [Published Motley Fool Discussion Boards - Sep 10 2014]
Cancer Drugs Fund is just smoke and mirrors [Published Pharma Times - Sep 10 2014]
Johnson & Johnson Should Ignore Those Breakup C... [Published ShoreLine Times - Sep 09 2014]
Johnson & Johnson Should Ignore Those Breakup C... [Published TheStreet.com - Sep 09 2014]
Johnson & Johnson Should Ignore Those Breakup C... [Published The Street Latest - Sep 09 2014]
Johnson & Johnson: The One Stock You Should Eve... [Published Seeking Alpha - Sep 09 2014]
1 2 3 4 5
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 06 2014]
Big Pharma Needs Growth: Two Severely Undervalu... [Published Wall St. Cheat Sheet - Jul 05 2014]
Source: Thinkstock At any given moment, there are literally hundreds of severely undervalued companies that are ripe for takeovers. In this article, I will focus on the pharmaceutical industry, where many investors have borth struck it rich when ...
Inside the Lobbyist War on Drug Prices: What In... [Published Wall St. Cheat Sheet - Jun 10 2014]
Source: Getty Images The pharmaceutical and biotech industries are notoriously tricky for investors. The industry is riskier than many others (such as basic materials or consumer goods), and companies’ successes are largely based on drug approvals, ...
Which of These 10 Best Selling Cancer Drugs Are... [Published Wall St. Cheat Sheet - Jun 06 2014]
Source: Thinkstock If you look at the pharmaceutical industry’s most promising investigational drugs (which you can do right here ), cancer therapies comprise the vast majority of the industry’s recent innovations; a fact which is increasingly important ...
IMAAGEN Data Demonstrate that Abiraterone Aceta... [Published PR Newswire: Health - Jun 02 2014]
HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use ...
1 2 3
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.